1067704

Betamethasone dipropionate

United States Pharmacopeia (USP) Reference Standard

• Synonyme(s) : Betamethasone 17,21-dipropionate, 9α-Fluoro-16β-methyl-11β,17α,21-trihydroxy-1,4-pregnadiene-3,20-dione 17,21-dipropionate
• Formule empirique (notation de Hill): C₂₈H₃₇FO₇
• Numéro CAS: 5593-20-4
• Poids moléculaire : 504.59
• Numéro MDL: MFCD00133140
• Code UNSPSC : 41116107
• ID de substance PubChem : 329748933
• Nomenclature NACRES : NA.24

Propriétés

• Qualité: pharmaceutical primary standard
• Famille d'API: betamethasone
• Fabricant/nom de marque: USP
• Application(s): pharmaceutical (small molecule)
• Format: neat
• Chaîne SMILES: [H][C@@]12C[C@H](C)[C@](OC(=O)CCl)(C(=O)COC(=O)CC)[C@@]1(C)C[C@H](O)C3(F)[C@@]2([H])CCC4=CC(=O)C=C[C@]34C
• InChI: 1S/C27H34ClFO7/c1-5-22(33)35-14-21(32)27(36-23(34)13-28)15(2)10-19-18-7-6-16-11-17(30)8-9-24(16,3)26(18,29)20(31)12-25(19,27)4/h8-9,11,15,18-20,31H,5-7,10,12-14H2,1-4H3/t15-,18-,19-,20-,24-,25-,26?,27-/m0/s1
• Clé InChI: UOCNBCVPZWLUKX-HOBFILNXSA-N

Description

Description générale

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

• Efficacy in Alopecia Areata Treatment: A study compared the effectiveness of topical betamethasone dipropionate with minoxidil in treating alopecia areata, highlighting its potent anti-inflammatory properties and its role in promoting hair regrowth. This positions betamethasone dipropionate as a key component in dermatological research aimed at understanding and improving treatment modalities for hair loss conditions (Aslam et al., 2024).


• Post-Surgical Pain Management: Research demonstrated the utility of a cocktail containing betamethasone dipropionate in reducing pain and prolonging analgesic effects post-total knee arthroplasty. This study emphasizes the pharmacokinetic benefits of betamethasone dipropionate in clinical pain management, providing valuable insights for ongoing pharmacological innovations (Luo et al., 2024).


• Improvement in Plaque Psoriasis: Betamethasone dipropionate was analyzed for its effectiveness in treating plaque psoriasis when used as part of a calcipotriol/betamethasone aerosol foam. The results underscore its significant role as a glucocorticoid receptor agonist, enhancing therapeutic outcomes for patients with psoriasis, thereby solidifying its place in anti-inflammatory steroid studies and psoriasis treatment compounds (Gerdes et al., 2024).

Actions biochimiques/physiologiques

Betamethasone 17,21-dipropionate is a glucocorticoid with anti-inflammatory and immunosuppressive activity.

Remarque sur l'analyse

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

Autres remarques

Sales restrictions may apply.

Informations sur la sécurité

• Pictogrammes: GHS08
• Mention d'avertissement: Danger
• Mentions de danger: H360FD,H373
• Conseils de prudence: P202 - P260 - P280 - P308 + P313 - P405 - P501
• Classification des risques: Repr. 1B - STOT RE 2
• Organes cibles: Liver,Kidney,Endocrine system
• Code de la classe de stockage: 6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
• Classe de danger pour l'eau (WGK): WGK 2
• Point d'éclair (°F): Not applicable
• Point d'éclair (°C): Not applicable